In The News,
Alzheimer’s Diagnostic and Drug
Provided a coverage roadmap for a drug manufacturer developing a new disease-modifying therapy for Alzheimer’s. Supported efforts to understand the role of diagnostic coding, coverage, and payment, including national non-coverage for PET imaging and set strategy for Medicare and commercial payer engagement for treatment coverage and access in the U.S. Identified key payer influencers, including the MAC Contractor Advisory Committee (CAC) members.